Drug Interaction between Tyrosine Kinase Inhibitors and Antacids
In the past decade, Tyrosine kinase inhibitors (TKIs) have been approved as a treatment for hematologic malignancy and several types of cancers. Since then, they have been extensively prescribed due to their convenient route of administration as oral tablets. However, there are some concerns regarding drug-drug interactions, which may affect the efficiency of the treatment. Antacids, which are also prescribed for many cancer patients during treatment, can increase gastric pH and decrease TKIs solubility, bioavailability, and treatment efficacy. The information concerning the uses of TKIs with antacids is still limited, and there is no standard recommendation regarding the combination use of both drugs for cancer treatments. Therefore, this review integrates pharmacological data and results from the combination-use trial to provide a guideline for using both drugs that minimize drug-drug interactions and retain the TKIs treatment's efficiency.
Weingart SN, Flug J, Brouillard D. Oral chemotherapy safety practices at US cancer centres:questionnaire survey.BMJ 2007;334:407.
Van LRW, Van GT, Mathijssen RH. Drug-drug interactions with tyrosine kinase inhibitors: a clinical perspective. Lancet Oncol 2014;15:315-26.
Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353:172-87.
Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005;315:971-9.
Sugano K. Computational oral absorption simulation of free base drugs. Int J Pharm 2010; 398:73-82.
Budha NR, Frymoyer A, Smelick GS, Jin JY, Yago MR, Dresser MJ, et al. Drug absorption interaction between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy. Clin Pharmacol Ther 2012;92:203-13.
Wienkers LC. Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 2005:4825-33.
International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010;9:215-36.
Smelick GS, Heffron TP, Chu L, Dean B, West DA, Duvall SL, et al. Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical develop-ment. Mol Pharm 2013;10:4055-62.
Gay C, Toulet D, Corre PL. Pharmacokinetic drug‐drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy. Hematol Oncol 2017;35:259-80.
Hunfeld NG, Touw DJ, Mathot RA, van Schaik RH, Kuipers EJ. A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther 2012;35:810-8.
Hunfeld NG, Touw DJ, Mathot RA, Mulder PG, Van Schaik RH, Kuipers EJ, et al. A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism. Aliment Pharmacol Ther 2010;31:150-9.
Sachs G, Shin JM, Briving C, Wallmark B, Hersey S. The pharmacology of the gastric acid pump: the H+,K+ ATPase. Annu Rev Pharmacol Toxicol 1995;35:277-305.
Jansen PA, Brouwers JR. Clinical pharmacology in old persons. Scientfica (Cairo) 2012; 2012:723678. Doi: 10.6064/2012/723678. PubMed PMID: 24278735 PubMed Central PMCID: PMC 38 20465
Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. Clin Oncol 2005;23:5474-83.
Lau YY, Gu W, Lin T, Viraswami-Appanna K, Cai C, Scott JW, et al. Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer. Cancer Chemother Pharmacol 2017;79:1119-28.
Tang W, Tomkinson H, Masson E. Effect of Sustained Elevated Gastric pH Levels on Gefitinib Exposure. Clin Pharmacol Drug Dev 2017;6:517-23.
Egorin MJ, Shah DD, Christner SM, Yerk MA, Komazec KA, Appleman LR, et al. Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. Br. J. Clin. Pharmacol. 2009;68: 370-4.
Koch KM, Im YH, Kim SB, Urruticoechea Ribate A, Stephenson J, Botbyl J, et al. Effects of Esomeprazole on the Pharmacokinetics of Lapatinib in Breast Cancer Patients. Clin Pharmacol Drug Dev 2013;2:336-41.
Yin OQ, Gallagher N, Fischer D, Demirhan E, Zhou W, Golor G, et al. Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. J. Clin. Pharmacol 2010;50:960-7.
Yin OQ, Giles FJ, Baccarani M, le Coutre P, Chiparus O, Gallagher N, et al. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol 2012;70:345-50.
McAlister RK, Aston J, Pollack M, Du L, Koyama T, Chism DD. Effect of concomitant pH-elevating medications with pazopanib on progression-free survival and cverall survival in patients with metastatic renal cell carcinoma. Oncologist 2018;23:686‐92.
Chen YM, Lai CH, Chang HC, Chao TY, Tseng CC, Fang WF, et al. Antacid use and de novo brain metastases in patients with epidermal growth factor receptor-mutant non-small cell lung cancer who were treated using first-line first-generation epidermal growth factor receptor tyrosine kinase inhibitors. PLoS One.2016 Feb 19;11:e0149722. Doi: 10.1371/journal.pone.0149722. PubMed PMID: 26894507; PubMed Central PMCID: PMC4760710
Lalani AKA. McKay RR. Lin X. Proton pump inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clinical Genitourinary Cancer 2017;15:724-32.
Sharma M. Holmes HM. Mehta HB. The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer. Cancer 2019;125:1155-62.
Keller KL, Franquiz MJ, Duffy AP, Trovato JA. Drug-drug interactions in patients receiving tyrosine kinase inhibitors. J Oncol Pharm Pract 2018;24:110-5.
Copyright (c) 2021 Thailand's National Cancer Institute Foundation
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความทีตีพิมพ์ในวารสารโรคมะเร็งนี้ถือว่าเป็นลิขสิทธิ์ของมูลนิธิสถาบันมะเร็งแห่งชาติ และผลงานวิชาการหรือวิจัยของคณะผู้เขียน ไม่ใช่ความคิดเห็นของบรรณาธิการหรือผู้จัดทํา